Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
ALX Oncology Holdings Inc. (ALXO) had Consolidated Net Income/Loss of $-22.14M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-22.14M |
|
-- |
|
-- |
|
$22.53M |
|
$-22.53M |
|
$0.39M |
|
$-22.14M |
|
$-22.14M |
|
$-22.14M |
|
$-22.14M |
|
|
Consolidated Net Income/Loss |
$-22.14M |
$-22.14M |
|
$-22.53M |
|
$-22.53M |
|
53.58M |
|
53.58M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$66.52M |
|
$1.35M |
|
$16.21M |
|
$82.72M |
|
$27.72M |
|
$5.76M |
|
$10.20M |
|
$37.92M |
|
$44.80M |
|
$44.80M |
|
$44.80M |
|
53.58M |
|
| Cash Flow Statement Financials | |
$-65.16M |
|
$71.35M |
|
$-0.32M |
|
$17.63M |
|
$23.51M |
|
$5.88M |
|
$9.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.40 |
|
-- |
|
-- |
|
0.11 |
|
0.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-65.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-49.43% |
|
-49.43% |
|
-26.77% |
|
-43.79% |
|
$0.84 |
|
$-1.22 |
|
$-1.22 |
|